What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
Key Points
Siren sold 235,862 shares of Ascendis Pharma in the first quarter; the estimated transaction value was $52.87 million based on quarterly average pricing.
Meanwhile, the quarter-end position value declined by $50.30 million, reflecting both trading activity and stock price movement.
The move represents a 1.47% shift in 13F reportable assets under management (AUM).
- 10 stocks we like better than Ascendis Pharma A/s ›
On May 14, 2026, Siren disclosed in an SEC filing that it sold its entire holding of Ascendis Pharma A/S (NASDAQ:ASND), liquidating 235,862 shares in an estimated $52.87 million transaction based on quarterly average pricing.
What happened
According to a SEC filing dated May 14, 2026, Siren sold its entire holding of 235,862 Ascendis Pharma A/S shares. The estimated transaction value is $52.87 million, calculated using the average share price during the first quarter of 2026. The fund’s quarter-end position in Ascendis Pharma A/S fell by $50.30 million, a figure that includes both the sale and price effects.
What else to know
- Top holdings after this filing:
- NASDAQ: SRRK: $532.16 million (14.8% of AUM)
- NASDAQ: KYMR: $265.43 million (7.4% of AUM)
- NASDAQ: ERAS: $181.93 million (5.0% of AUM)
- NASDAQ: EWTX: $139.55 million (3.9% of AUM)
- NASDAQ: ONC: $138.09 million (3.8% of AUM)
- As of May 13, 2026, shares of Ascendis Pharma A/S were priced at $243.58, up 50% over the past year and outperforming the S&P 500 by 24 percentage points.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 2026-05-13) | $243.58 |
| Market Capitalization | $15 billion |
| Revenue (TTM) | $865.8 million |
| Net Income (TTM) | ($459.9 million) |
Company snapshot
- Ascendis Pharma A/S develops and markets therapeutics for unmet medical needs, with key products including SKYTROFA for growth hormone deficiency and a pipeline of TransCon technology-based candidates targeting endocrine and rare diseases.
- Ascendis Pharma A/S generates revenue through the sale of approved biopharmaceutical products.
- Headquartered in Denmark, the company employs over 1,000 people and focuses on long-acting therapies for rare endocrine and pediatric diseases.
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark, focused on innovative therapies for rare endocrine and pediatric diseases. The company leverages its TransCon technology platform to develop long-acting prodrugs that address significant unmet medical needs.
What this transaction means for investors
Ascendis stock has climbed 50% over the past year as investors piled into the company’s growing rare disease franchise and improving financial picture, but this sale doesn’t necessarily seem like it’s a vote against the firm’s business.
The timing is notable because Ascendis just posted one of its strongest quarters yet. First-quarter revenue more than doubled to 247 million euros, driven largely by 197 million euros in YORVIPATH sales, while SKYTROFA contributed another 44 million euros. The company also said more than 1,000 new patients enrolled for YORVIPATH in the U.S. during the quarter, while the achondroplasia drug YUVIWEL had already added more than 60 patients by May 1 (after its U.S. commercial launch in early April).
Ascendis also swung to a reported quarterly net profit of 629 million euros, though that figure was heavily boosted by the recognition of a deferred tax asset. Ultimately, what may matter most is whether Ascendis can keep converting rare disease momentum into sustainable cash flow growth. The pipeline looks increasingly credible, but after a strong rally, expectations are much higher.
Should you buy stock in Ascendis Pharma A/s right now?
Before you buy stock in Ascendis Pharma A/s, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ascendis Pharma A/s wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,205!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,384,459!*
Now, it’s worth noting Stock Advisor’s total average return is 999% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 14, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Ascendis Pharma A/s and BeOne Medicines Ag. The Motley Fool recommends Kymera Therapeutics. The Motley Fool has a disclosure policy.
Recommended Articles
